Drug Use-Results Survey of ELEVIDYS for Injection (All-Patient Surveillance)

Drug Use-Results Survey of ELEVIDYS for Injection (All-Patient Surveillance) - Drug Use-Results Survey of ELEVIDYS for Injection (All-Patient Surveillance)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060690

Enrollment

Registered

2026-02-17

Start date

2026-02-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne Muscular Dystrophy

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients who are scheduled to receive this product until a decision is made on the new approval application within the time limit of conditional and time-limited approval. If a patient receiving this product transfers to another hospital (including cases where they are concurrently examined for Duchenne Muscular Dystrophy (DMD) at another facility) during the observation period, registration should also be conducted at the transfer destination medical institution.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Presence of adverse events, event name, onset date, worst Grade, severity, treatment, outcome, outcome date, causality	—

Countries

Japan

Contacts

Public ContactAyako Murayama

Chugai Pharmaceutical Co. Ltd. Safety science 2 Dept.

murayamaayk@chugai-pharm.co.jp03-3281-6611

Outcome results